Skip to main content
Media RelationsInvestor RelationsHome
Logo SphingotecLogo Sphingotec

The Biomarker Company

SphingoTec develops and markets innovative IVD solutions for novel and proprietary blood-based protein biomarkers. Our aspiration is to effectively translate scientific advancements into routine clinical practice.

Our innovative biomarkers address diagnostically underserved acute and critical care conditions such as acute kidney injury, sepsis, and acute heart failure. The solutions we have created combine scientific discoveries with medical research and robust technologies to support clinicians in improving patient care. We work with internationally leading academic and non-academic medical centers as well as global IVD and pharma companies to bring these innovations closer to the patients. 

Innovative diagnostic solutions for unmet medical needs

Wide adoption

Commercial opportunities

We collaborate with a wide range of industry partners to convey the value of our biomarker innovations in clinical diagnostics and drug development.

Read more

Product portfolio

Biomarker-based diagnostics

We make our proprietary biomarkers available as CE IVD microtiter plate assays, a well-established technique suited for laboratories. 

Read more

From bench to bedside

Biomarker innovations

The main mortality drivers in intensive care units are diagnostic blind spots. We pave the way for early intervention and personalized medicine in acute and critical care with innovative biomarkers.

 

Read more

Latest News

View all News

09. May 2023

SphingoTec's Innovative IVD Product sphingotest® penKid® Receives First IVDR Certificate

SphingoTec has been successfully re-certified according to ISO 13485 and received its first IVDR certificate for its IVD product sphingotest® penKid®.
Read more
04. April 2023

ADQI Group Recognizes PenKid as Relevant Functional Biomarker for Sepsis-Associated Acute Kidney Injury

The Acute Disease Quality Initiative (ADQI) has published a consensus statement that strongly recommends using innovative biomarkers to improve the management of sepsis-associated acute kidney injury (SA-AKI).
Read more
23. February 2023

SphingoTec Appoints Dr. Florian Uhle as Medical Director

Diagnostic company SphingoTec is pleased to announce the appointment of Dr. Florian Uhle as the company's new Medical Director. Dr. Uhle is a subject matter expert in translating innovations into routine clinical practice with a broad experience in both clinical and corporate settings.
Read more

Events & Expos

View all Events

05. - 08. October 2023

14:04 - 15:05

Berlin, Germany

Kongress für Nephrologie 2023

The Forum Nephrologie is a scientific, educational, and networking meeting and part of the 15. Jahrestagung der DGfN. The main congress program will kick off with an opening ceremony on Thursday,…

Read more
14. - 16. June 2023

14:00 - 15:01

Berlin, Germany

54. Gemeinsame Jahrestagung DGIIN & ÖGIAIN 2023

We are looking forward to participating for the first time in the 54th Joint Annual Meeting of the German Society of Internal Intensive Care and Emergency Medicine (DGIIN) and the Austrian Society of…

Read more
29. March - 01. April 2023

11:33 - 13:34

San Diego, USA

The 28th International Conference on Advances in Critical Care Nephrology AKI & CRRT 2023

The CRRT conference provides a comprehensive review of advances in clinical care, research, and technology in critical care medicine with a focus on the kidney and renal support techniques. We are…

Read more

Subscribe to our Newsletter

Follow the link below to subscribe to our Newsletter & receive updates on our company and products

Subscribe now

Follow our Journey on Social Media